mutant glioma/glioblastoma model systems [7] . The IDH1 mutation is particularly common in secondary glioblastomas and low-grade gliomas, such as oligodendrogliomas and the IDH1 R132H mutation can be readily detected by immunohistochemistry on patient samples. Moreover, tumors, harboring the IDH1 mutation, display an accumulation of an oncometabolite, 2-R-2-hydroxyglutarate (2-HG), which can reach levels in the millimolar range. Concerning the prognosis of glioma patients, presence of the IDH1 mutation was shown to be related to a significantly prolonged survival. The present literature suggests that many features of IDH mutant gliomas are in fact mediated by 2-HG, e.g. the generation of a hypermethylated phenotype, CIMP.
We have found that IDH1 mutated astrocytoma specimens display lower protein levels of Mcl-1 as compared to IDH1 wild-type samples. Similarly, genetically engineered cell lines of mutated IDH1 R132H showed lower levels of Mcl-1. Utilizing chemically synthesized 2-HG that has been engineered to penetrate the cell membrane, we found that physiologically relevant concentrations of 2-HG (at levels that are encountered in tumors) down-regulated Mcl-1 protein levels as well. Consequently, both 2-HG and IDH1 R132H enhanced apoptosis by Bcl-xL inhibition as well as by the BH3-mimetic, ABT263, in multiple glioma model systems. Interestingly, neither IDH1 R132H nor 2-HG sensitized for Bcl-2 inhibition mediated by the selective BH3-mimetic, ABT199, suggesting that Bcl-xL indeed mediates the synthetic lethal interaction in the context of glioma. Our results should be seen in context of another recently published paper that has observed that Bcl-2 and Bcl-w inhibition is synthetically lethal in IDH-mutant model systems of acute myeloid leukemia, which was derived from a genome-wide lentiviral shRNA library screen [8] . Akin to gliomas, AML often harbor the IDH1 mutation as well.
Our results show that IDH1 R132H and 2-HG interfere with tumor cell metabolism and demonstrate that IDH1 R132H and 2-HG suppress energy production via oxidative phosphorylation, which subsequently leads to a decline in energy levels ( Figure 1) . However, the precise underlying mechanism as to how 2-HG regulates oxidative phosphorylation remains to be determined. Some evidence suggests that it may involve a direct enzymatic inhibition of respiratory complexes. However, it is conceivable that Mcl-1 itself might have an impact on cellular respiration as well since some pools of Mcl-1 localize to the mitochondrial matrix. Another hypothesis is that the hypermethylated phenotype by IDH1 mutated gliomas contributes to these metabolic alterations. Low energy levels are often accompanied by a reduction of protein synthesis as this process requires energy delivering phosphoanhydride bonds in the form of tri-phospho nucleotides, such as GTP. Supporting this general notion, both 2-HG and IDH1 R132 lowered protein synthesis and hence the expression of proteins that have a short half-life, such as Mcl-1. In turn low levels of Mcl-1 prime tumor cells to apoptosis induction by Bcl-xL inhibition.
The appeal of this outlined approach is the potential selectivity for tumor cells and the fact that in the context of the recently revised WHO classification for central nervous system tumors IDH mutations are part of the standard diagnostic procedure for gliomas, thus ensuring that almost all mutations for IDH1 will be detected in the course of establishing a diagnosis. In summary, our work provides a foundation and justification for testing Bcl-xL inhibition in patients with IDH1 mutated gliomas.
